intra-striatal rAAV5-miHTT for huntington disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 6 Sep 2019: Trial started, NCT04120493
  2. 9 Oct 2019: Trial registered, NCT04120493
  3. 7 Oct 2021: Trial started, NCT05243017
  4. 16 Feb 2022: Trial registered, NCT05243017

The trials

NCT04120493: Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease

State
Under way
Phase
Phase 1 and Phase 2
People
43 planned
Started
6 Sep 2019
Primary completion
Jun 2029
Arms
Cohort 1, Cohort 2, Cohort 3, Cohort 4
Results
None posted
  1. 6 Sep 2019: Trial started
  2. 9 Oct 2019: Trial registered

NCT05243017: Safety and Efficacy of AMT-130 in European Adults With Early Manifest Huntington's Disease

State
Under way
Phase
Phase 1 and Phase 2
People
14 taking part
Started
7 Oct 2021
Primary completion
Mar 2029
Arms
Cohort 1, Cohort 2, Cohort 3
Results
None posted
  1. 7 Oct 2021: Trial started
  2. 16 Feb 2022: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Gene therapy.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.